Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12610000178044
Ethics application status
Approved
Date submitted
19/02/2010
Date registered
26/02/2010
Date last updated
11/07/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase I, pharmacokinetic trial, in healthy Asian and Caucasian volunteers for investigating the pharmacokinetic profiles of Eurartesim (trademark) (40 mg Dihydroartemisinin/320 mg Piperaquine Phosphate)
Scientific title
A phase 1 pharmacokinetic trial in healthy Asian and Caucasian volunteers, investigating the pharmacokinetic profile of an Anti-Malarial drug - 40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine Phosphate (PQP).
Secondary ID [1] 1437 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anti-Malarial
Treatment of uncomplicated plasmodium falciparum malaria 256857 0
Condition category
Condition code
Infection 257006 257006 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Eurartesim (trademark) is a fixed dose combination tablet for oral administration.
Each tablet contains 40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine Phosphate (PQP)
On the study each subject recieves either three or four tablets daily for three consecutive days. The tablets are to be administered following a light breakfast (30 g cornflakes and 250 mL fullfat milk).

The number of tablets administered is calculated using the subjects body weight - subjects weighing less than 75 kg are prescribed three tablets and subjects weighing greater than 75 kg are prescribed four tablets.
Intervention code [1] 256050 0
Prevention
Intervention code [2] 256072 0
Treatment: Drugs
Comparator / control treatment
There is no comparator or control group- all subjects receive the same active treatment- the study is comparing the pharmacokinetics across gender, body weight and asian v caucasian.
Control group
Active

Outcomes
Primary outcome [1] 257903 0
To compare the pharmacokinetics of Dihydroartemisinin (DHA) and Piperaquine (PQ) between subjects grouped by ethnic
origin (i.e. Caucasian vs Asian).

This objective will be evaluated by comparison of the pharmacokinetics (PK) profile of 24 Caucasian subjects with a body
weight of less than or equal to 65 kg vs the pharmacokinetics (PK) profile of 24 Asian subjects with a body weight of less than or equal to 65 kg.
Timepoint [1] 257903 0
Screening: Up to 21 days prior to first dose

Dosing Period: Subjects are confined to the clincial unit from the evening of Day -1 to the evening of Day 3, and will receive dosing on Days 0, 1 and 2. (Days are calculated as Day -1, Day 0, Day 1,2,3 etc)

Follow-up Period: Subjects are to return to the clinical unit on the following days for the collection of pharmacokinetic samples and saftey checks- Days 4,5,7,14,21,28,42,56 and 90.
Secondary outcome [1] 263360 0
To compare the pharmacokinetics of Dihydroartemisinin (DHA) and Piperaquine (PQ) between subjects grouped by body
weight (i.e. subjects below 65 kg vs subjects above 65 kg) for Caucasian subjects.
This objective will be evaluated by comparison of the pharmacokinetics (PK) profile of 24 Caucasian subjects with a body
weight of 65 kg vs the PK profile of 24 Caucasian subjects with a body weight > 65 kg and correlation
analysis between pharmacokinetics (PK) and body weight among the subjects of Caucasian origin.
Timepoint [1] 263360 0
Screening: Up to 21 days prior to first dose

Dosing Period: Subjects are confined to the clincial unit from the evening of Day -1 to the evening of Day 3, and will receive dosing on Days 0, 1 and 2. (Days are calculated as Day -1, Day 0, Day 1,2,3 etc)

Follow-up Period: Subjects are to return to the clinical unit on the following days for the collection of pharmacokinetic samples and saftey checks- Days 4,5,7,14,21,28,42,56 and 90.

Total duration that the subject will be involved in the study (from first visit to last visit) will be approximately 16 weeks.
Secondary outcome [2] 263361 0
To compare the pharmacokinetics of DHA and PQ between subjects grouped by gender.
This objective will be evaluated by comparison of the PK profile of 24 male subjects with a body
weight less than 65 kg vs the PK profile of 24 female subjects.
Timepoint [2] 263361 0
Screening: Up to 21 days prior to first dose

Dosing Period: Subjects are confined to the clincial unit from the evening of Day -1 to the evening of Day 3, and will receive dosing on Days 0, 1 and 2. (Days are calculated as Day -1, Day 0, Day 1,2,3 etc)

Follow-up Period: Subjects are to return to the clinical unit on the following days for the collection of pharmacokinetic samples and saftey checks- Days 4,5,7,14,21,28,42,56 and 90.
Secondary outcome [3] 263362 0
To compare the safety of Eurartesim between subjects grouped by dose level.

This objective will be evaluated by comparison of the incidence of adverse events, including changes
in physical examinations, vital signs, electrocardiograph (ECG) assessments and clinical laboratory tests, grouped by dose
level (3 or 4 tablets).
Timepoint [3] 263362 0
Screening: Up to 21 days prior to first dose

Dosing Period: Subjects are confined to the clincial unit from the evening of Day -1 to the evening of Day 3, and will receive dosing on Days 0, 1 and 2. (Days are calculated as Day -1, Day 0, Day 1,2,3 etc)

Follow-up Period: Subjects are to return to the clinical unit on the following days for the collection of pharmacokinetic samples and saftey checks- Days 4,5,7,14,21,28,42,56 and 90.

Eligibility
Key inclusion criteria
1. Male or female, aged between 18 and 50 years (inclusive).
2. Caucasian or Asian (excluding Indian sub-continent or Middle Eastern origin).
3. Healthy subjects - healthy subjects are defined as individuals who are free from clinically
significant illness or disease as determined by their medical/surgical history, physical
examination (including height and weight), vital signs, 12-lead ECG and clinical laboratory
determinations.
4. Adequate venous access in the left or right arm to allow collection of a number of blood
samples.
5. Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum
body weight of 36 kg.
6. Agrees to use two approved methods of contraception (excluding post menopausal females
and males and females who underwent surgical sterilization at least six months prior to
dosing) from Screening and until 90 days after administration of the study drug. Methods
of contraception for use by the subject or partner (as applicable) may include condom,
approved birth control pills, patches, implants or injections, diaphragm with vaginal
spermacide, an IUD (intra uterine device).
7. Have given written informed consent to participate in this study in accordance with local
regulations.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Have received or is anticipated to receive a prescription medication within 14 days prior to
the start of dosing or an over-the-counter medicine 48 hours prior to the start of dosing.
2. Any condition that would interfere with drug absorption (e.g. chronic diarrhoea).
ST3073/ST3074-DM09-007
Final Version 3.0 of 03 Feb 2010 18/61
3. Be pregnant or lactating (females only).
4. Abnormal laboratory test results deemed clinically significant by the Medical Officer
(Principal Investigator or medically qualified nominee).
5. Evidence of significant renal insufficiency, as indicated by an estimated creatinine
clearance using the Cockcroft-Gault formula of less than 75 mL/min at Screening.
6. As a result of medical review, physical examination (including height and weight) or
Screening investigations, the Medical Officer considers the subject unfit for the study.
7. Positive urine drug test or alcohol breath test.
8. History or clinical evidence of oral, cardiovascular, cerebrovascular, haematological,
gastrointestinal, hepatic, renal, endocrine, pulmonary, neurological, psychiatric or skin
disorder, which in the opinion of the Investigator would compromise the participant’s
safety or other aspects of the study.
9. Acute therapy for a serious infection within 30 days of study entry.
10. History of significant drug allergies or significant allergic reaction or currently suffers from
clinically significant systemic allergic disease.
11. Positive Screening test for Hepatitis B surface antigen or Hepatitis C antibody or HIV
(human immunodeficiency virus).
12. Have participated in a clinical trial or have received an experimental therapy within 30
days or 10 half-lives of the drug, whichever is the longer, prior to dosing.
13. Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within
90 days before the first dose administration.
14. Regularly drink more than four (4) units (for males) and two (2) units (for females) of
alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit).
15. Unwilling to abide by the study restrictions listed in Section 8.3, including refraining from
smoking during the confinement period.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Subjects not randomised but stratified to dose group according to body weight (kg).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not Applicable
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Pharmacokinetics
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
15/02/2010
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment postcode(s) [1] 2598 0
3004
Recruitment postcode(s) [2] 2599 0
5000

Funding & Sponsors
Funding source category [1] 256553 0
Commercial sector/Industry
Name [1] 256553 0
Sigma-Tau i.f.r. S.p.A
Country [1] 256553 0
Italy
Primary sponsor type
Commercial sector/Industry
Name
CPR Pharma Services Pty Ltd
Address
Suite C, 32 West Thebarton Road
Thebarton SA 5031
Australia
Ph: +61-8-8125-1903
Fax: +61-8-8354-3146
Country
Australia
Secondary sponsor category [1] 255853 0
Commercial sector/Industry
Name [1] 255853 0
CPR Pharma Services Pty Ltd
Address [1] 255853 0
Suite C, 32 West Thebarton Road
Thebarton SA 5031
Australia
Ph: +61-8-8125-1903
Fax: +61-8-8354-3146
Country [1] 255853 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 258594 0
Bellberry Human Research Ethics Committee
Ethics committee address [1] 258594 0
229 Greenhill Road
Dulwich SA 5065
Ethics committee country [1] 258594 0
Australia
Date submitted for ethics approval [1] 258594 0
13/01/2010
Approval date [1] 258594 0
12/02/2010
Ethics approval number [1] 258594 0
C9/10

Summary
Brief summary
The purpose of this study is to test the safety of the drug Eurartesim (trademarked). The drug is to be used for the treatment of uncomplicated Plasmodium Falciparum (a type of malaria, a mosquito borne infectious disease). A number of safety studies have been completed for this new drug, but the company requires more information about what happens when taking this drug in certain groups of people, including the differences between men and women, and the differences between asian and caucasian (western) people and the difference in body weights ( particularly people weighing less than 65 kg and those weighing more than 65kg). The study is to be conducted in helathy people to comapre how the drug behaves in these groups.
Trial website
none
Trial related presentations / publications
none
Public notes

Contacts
Principal investigator
Name 30863 0
Address 30863 0
Country 30863 0
Phone 30863 0
Fax 30863 0
Email 30863 0
Contact person for public queries
Name 14110 0
Tamara Murdock
Address 14110 0
CPR Pharma Services Pty Ltd
Suite C, 32 West Thebarton Road
Thebarton SA 5031
Australia
Country 14110 0
Australia
Phone 14110 0
+61-8-8125-1906
Fax 14110 0
+61-8-8354-3146
Email 14110 0
[email protected]
Contact person for scientific queries
Name 5038 0
Tamara Murdock
Address 5038 0
CPR Pharma Services Pty Ltd
Suite C, 32 West Thebarton Road
Thebarton SA 5031
Australia
Country 5038 0
Australia
Phone 5038 0
+61-8-8125-1906
Fax 5038 0
+61-8-8354-3146
Email 5038 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.